Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 3

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  mycoses
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

Treatment of fungal infections of upper respiratory tract and ear

100%
Kurnatowski P., Agnieszka K. K.
Otolaryngologia Polska
|
2007
|
vol. 61(3)
280-285
EN
Fungi, in comparison with other pathogenic factors, have high pathogenecity. The number of fungal species which are able to infect people is over 500. The upper respiratory tract and ear have permanent contact with external environment which makes their ontocenoses open to continuous exchange of microorganisms of which they consist. In etiology of inflammatory processes 21 species which belonging to 3 genera (Zygomycota, Asomycota, Basidiomycota) of fungi play important role. Administration of antifungal drugs can be: prophylactic, empiric preemptive and therapeutic. Physicians may prescribe antibiotics (mainly poliens: amphotericin B, natamycin and nystatin) and chemiotherapeutics (mainly azoles and fluorpirymidins, pigments, chlorhexidine and chlorquinaldol). In ENT practice topical and systemic drugs can be administrated. Topical lozenges include amphotericin B, clotrimazole, chlorhexidine or chlorquinaldol and oral gels: nystatin and miconazole. Some of drugs are in the form of suspension/solution, which can be used for inhalation, into the sinus, for swabbing or for lavage: amphotericin B, natamycin, nystatin, clotrimazol, flucytosine, miconazole, fluconazole, vorykonazole, caspofungin. It should be underlined that only a few of dugs can be absorbed from the digestive tract: flucytosine, fluconazole, itraconazole, ketoconazole, miconazole, vorykonazole.
2
Publication available in full text mode
Content available

Nasal Mucormycosis: Our experience with 24 cases

75%
Bakshi S. S., Das S., Ramesh S., Gopalakrishnan S.
Otolaryngologia Polska
|
2020
|
vol. 74(4)
37-40
EN
Background: Mucormycosis is a rare fungal infection affecting people with impaired immunity. The aim of this study is to shed light on the epidemiology, incidence, and outcome of patients with mucormycosis hospitalized at a tertiary care center in Pondicherry. Methods: We conducted a retrospective chart review between January 2008 and January 2018. All patients with proven or probable mucormycosis were included. Results: A total of 24 patients were included. Their median age was 49 years and the majority were males. Comorbidities included mainly hematologic malignancy and diabetes mellitus. A liposomal amphotericin B formulation alone or in combination with other antifungals was used as a first line agent in all patients. Conclusion: The incidence of mucormycosis has significantly increased over the past 10 years at our institution, most likely due to increased risk factors.
3
Publication available in full text mode
Content available

Nasal Mucormycosis: Our experience with 24 cases

75%
Bakshi S. S., Das S., Ramesh S., Gopalakrishnan S.
Polish Journal of Otolaryngology
|
2020
|
vol. 74
|
issue 4
37-40
EN
Background: Mucormycosis is a rare fungal infection affecting people with impaired immunity. The aim of this study is to shed light on the epidemiology, incidence, and outcome of patients with mucormycosis hospitalized at a tertiary care center in Pondicherry. Methods: We conducted a retrospective chart review between January 2008 and January 2018. All patients with proven or probable mucormycosis were included. Results: A total of 24 patients were included. Their median age was 49 years and the majority were males. Comorbidities included mainly hematologic malignancy and diabetes mellitus. A liposomal amphotericin B formulation alone or in combination with other antifungals was used as a first line agent in all patients. Conclusion: The incidence of mucormycosis has significantly increased over the past 10 years at our institution, most likely due to increased risk factors.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.